

lurasidone (Latuda)

Disclaimer

Clinical guidelines are developed and adopted to establish evidence-based clinical criteria for utilization management decisions. Clinical guidelines are applicable according to policy and plan type. The Plan may delegate utilization management decisions of certain services to third parties who may develop and adopt their own clinical criteria.

Coverage of services is subject to the terms, conditions, and limitations of a member's policy, as well as applicable state and federal law. Clinical guidelines are also subject to in-force criteria such as the Centers for Medicare & Medicaid Services (CMS) national coverage determination (NCD) or local coverage determination (LCD) for Medicare Advantage plans. Please refer to the member's policy documents (e.g., Certificate/Evidence of Coverage, Schedule of Benefits, Plan Formulary) or contact the Plan to confirm coverage.

Summary

lurasidone (Latuda) is a second generation antipsychotic, also referred to as an atypical antipsychotic. It is FDA-approved for:

1. Treatment of schizophrenia in patients 13 years of age or older
2. Treatment of major depressive episodes associated with bipolar I disorder (bipolar depression) in patients 10 years of age or older

Bipolar depression and schizophrenia are different types of mental health conditions. Treatment plans for both conditions usually include both drug and non-drug treatments. Medicines, such as lurasidone (Latuda), are often a part of treatment for both bipolar depression and schizophrenia. Other medications in the group of second generation antipsychotics include, but are not limited to aripiprazole, olanzapine, quetiapine, risperidone, and ziprasidone. Tolerance and response to antipsychotic agents vary, and patients who do not tolerate or respond to a specific agent may be treated with a different agent and expect a different response or adverse effect(s). The choice of an antipsychotic agent depends on a

multitude of factors, including but not limited to response (or lack thereof) to previously used medications, safety and tolerability of each agent, and patient-specific considerations.

Definitions

“Bipolar 1 Disorder” is a mental health condition which includes episodes of emotional highs (mania) and lows (depression). It may cause extreme changes in behavior and mood, such as feeling much happier or sadder than normal.

“Schizophrenia” is a psychiatric disorder involving chronic or recurrent psychosis and is commonly associated with impairments in social and occupational functioning.

“Schizoaffective disorder (ScAD)” is a mental health condition which has both psychotic symptoms and mood (affective) disorder symptoms. People with ScAD may have symptoms of depression (e.g., feeling sad, empty) or mania (e.g., raised mood, feel powerful and can do anything).

Medical Necessity Criteria for Initial Authorization

The Plan considers lurasidone (Latuda) medically necessary when **ALL** the following criteria are met for the applicable indication listed below:

For the treatment of Depressive Episodes Associated with Bipolar Disorder:

1. The requested medication is prescribed by or in consultation with a psychiatrist; **AND**
2. The member is at least 10 years of age; **AND**
3. The member has a diagnosis of bipolar disorder; **AND**
4. The member meets **ONE** (1) of the following:
 - a. is unable to use or has adequately tried and failed at least a one-month trial to **BOTH** of the following:
 - i. quetiapine immediate-release or extended-release; **and**
 - ii. olanzapine and fluoxetine in combination; **or**
 - b. is at higher risk of metabolic abnormalities (e.g., those with diabetes mellitus or hyperlipidemia); **AND**
5. Clinical chart documentation is provided for review to substantiate the above listed requirements.

For the treatment of Schizophrenia:

1. The requested medication is prescribed by or in consultation with a psychiatrist; **AND**
2. The member is 13 years of age or older; **AND**
3. The member has a diagnosis of schizophrenia; **AND**
4. The member is unable to use or has adequately tried and failed at least a one-month trial to **TWO** (2) of the following:
 - a. Aripiprazole; **and/or**
 - b. Olanzapine; **and/or**
 - c. Risperidone; **and/or**
 - d. Paliperidone; **and/or**
 - e. Quetiapine; **and/or**
 - f. Ziprasidone; **AND**
5. Clinical chart documentation is provided for review to substantiate the above listed requirements.

For the treatment of Schizoaffective Disorder:

1. The requested medication is prescribed by or in consultation with a psychiatrist; **AND**
2. The member is 18 years of age or older; **AND**
3. The member has a diagnosis of schizoaffective disorder; **AND**
4. The member is unable to use or has adequately tried and failed at least a one-month trial to **BOTH** of the following:
 - a. Paliperidone; **and**
 - b. **ONE** of the following:
 - i. Aripiprazole; **or**
 - ii. Olanzapine; **or**
 - iii. Risperidone; **or**
 - iv. Quetiapine; **or**
 - v. Ziprasidone; **AND**
5. Clinical chart documentation is provided for review to substantiate the above listed requirements.

If the above prior authorization criteria are met for the applicable indication, lurasidone (Latuda) will be approved for 12 months.

Medical Necessity Criteria for Reauthorization

Reauthorization for 12 months will be granted if **BOTH** of the following are met:

1. chart documentation shows the member has experienced clinical response to the requested therapy as evidenced by one of the following:
 - a. clinical improvement (e.g., reduction in intensity or severity of symptoms) since starting the requested medication; **or**
 - b. stability in condition (e.g., stabilizing mood, return to normal psychosocial functioning) since starting the requested medication; **AND**
2. The member maintains adherence to the prescribed dosing regimen as evidenced by pharmacy claims record.

Experimental or Investigational / Not Medically Necessary

lurasidone (Latuda) for any other indication is considered not medically necessary by the Plan, as it is deemed to be experimental, investigational, or unproven.

References

1. Alonso-Pedrero L, Bes-Rastrollo M, Marti A. Effects of antidepressant and antipsychotic use on weight gain: A systematic review. *Obes Rev.* 2019;20(12):1680-1690. doi:10.1111/obr.12934
2. American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5)*, American Psychiatric Association, Arlington, VA 2013.
3. Arango C, Ng-Mak D, Finn E, Byrne A, Loebel A. Lurasidone compared to other atypical antipsychotic monotherapies for adolescent schizophrenia: a systematic literature review and network meta-analysis [published online November 22, 2019]. *Eur Child Adolesc Psychiatry.*
4. Aziz R. How to Choose an Antipsychotic in Schizophrenia. *The Carlat Psychiatry Report*, April 2020. Volume 18, Issue 4.
5. Bobo WV. The Diagnosis and Management of Bipolar I and II Disorders: Clinical Practice Update. *Mayo Clin Proc* 2017; 92:1532.
6. Carlat D. Latuda: An Evaluation of Its Usefulness. *The Carlat Psychiatry Report*, Feb 2015. Volume 13, Issue 2.
7. Citrome L, Weiden PJ, McEvoy JP, et al. Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: a 6-month, open-label, extension study. *CNS Spectr.* 2014;19(4):330-339.
8. Correll CU and Kane JM. Ranking Antipsychotics for Efficacy and Safety in Schizophrenia. *JAMA Psychiatry*, 2020; 77(3), p.225. doi:10.1001/jamapsychiatry.2019.3377
9. Cruz N, Sanchez-Moreno J, Torres F, Goikolea JM, Valentí M, Vieta E. Efficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: a meta-analysis. *Int J Neuropsychopharmacol.* 2010;13(1):5-14. doi:10.1017/S1461145709990344

10. Dayabandara M, Hanwella R, Ratnatunga S, Seneviratne S, Suraweera C, de Silva VA. Antipsychotic-associated weight gain: management strategies and impact on treatment adherence. *Neuropsychiatr Dis Treat*. 2017;13:2231-2241. doi:10.2147/NDT.S113099
11. DelBello MP, Goldman R, Phillips D, Deng L, Cucchiaro J, Loebel A. Efficacy and safety of lurasidone in children and adolescents with bipolar I depression: a double-blind, placebo-controlled study. *J Am Acad Child Adolesc Psychiatry*. 2017;56(12):1015-1025.
12. Grunze H, Vieta E, Goodwin GM, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: acute and long-term treatment of mixed states in bipolar disorder. *World J Biol Psychiatry*. 2018;19(1):2-58. doi:10.1080/15622975.2017.1384850
13. Hasan A, Falkai P, Wobrock T, et al; World Federation of Societies of Biological Psychiatry (WFSBP) Task Force on Treatment Guidelines for Schizophrenia. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. *World J Biol Psychiatry*. 2012;13(5):318-378. doi:10.3109/15622975.2012.696143
14. Javed A, Arthur H, Curtis L, Hansen L, Pappa S. Practical guidance on the use of lurasidone for the treatment of adults with schizophrenia. *Neurol Ther*. 2019;8(2):215-230. doi:10.1007/s40120-019-0138-z
15. Jena M, Mishra A, Mishra BR, Nath S, Maiti R. Effect of lurasidone versus olanzapine on cardiometabolic parameters in unmedicated patients with schizophrenia: a randomized controlled trial. *Psychopharmacology (Berl)*. 2020;237(11):3471-3480. doi:10.1007/s00213-020-05628-3
16. Judd LL, Akiskal HS, Schettler PJ, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. *Arch Gen Psychiatry* 2002; 59:530.
17. Keepers GA, Fochtmann LJ, Anzia JM, et al. The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. *Am J Psychiatry*. 2020;177(9):868-872. doi:10.1176/appi.ajp.2020.177901
18. Latuda (lurasidone) [prescribing information]. Marlborough, MA: Sunovion Pharmaceuticals Inc; May 2022.
19. Lehman AF, Lieberman JA, Dixon LB, et al; American Psychiatric Association; Steering Committee on Practice Guidelines. Practice guideline for the treatment of patients with schizophrenia, second edition. *Am J Psychiatry*. 2004;161(2)(suppl):1-56.
20. Miller JN, Black DW. Schizoaffective disorder: a review. *Ann Clin Psychiatry*. 2019; 31(1):47-53.
21. Muñoz-Negro JE, Cuadrado L, Cervilla JA. Current Evidences on Psychopharmacology of Schizoaffective Disorder. *Actas Esp Psiquiatr*. 2019; 47(5):190-201.
22. National Institute for Health and Clinical Excellence (NICE), National Collaborating Centre for Mental Health. Psychosis and schizophrenia in children and young people: recognition and management. 2013. <https://www.nice.org.uk/guidance/cg155>[PubMed 26065063]
23. Osser DN. The Psychopharmacology Algorithm Project at the Harvard South Shore Program: An update on management of behavioral and psychological symptoms in dementia. *Psychiatry Res*. 2021;295:113641. doi:10.1016/j.psychres.2020.113641
24. Stroup TS, Marder S. Schizophrenia in adults: maintenance therapy and side effect management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <http://www.uptodate.com>. Accessed June 21, 2022.
25. Yatham LN, Chakrabarty T, Bond DJ, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) recommendations for the

management of patients with bipolar disorder with mixed presentations. *Bipolar Disord.* 2021;23(8):767-788. doi:10.1111/bdi.13135

26. Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. *Bipolar Disord.* 2018;20(2):97-170. doi:10.1111/bdi.12609

Clinical Guideline Revision / History Information

Original Date: 11/05/2020

Reviewed/Revised: 10/14/2021, 12/01/2021, 9/15/2022, 9/21/2023